Immunotherapy, enabling a patient's own immune system to attack a cancer, is a novel treatment modality that has shown activity in more than 20 cancer types. Head and neck cancers show a prominent inflamed phenotype with tumor infiltrating lymphocytes, and is amenable to immunotherapy. Specifically, immune checkpoint inhibitors, such as those blocking the interaction of PD-1 and PD-L1 have shown marked activity in recurrent/metastatic head and neck cancer, including oral cavity tumors. Responses are oftentimes more durable than what is observed with chemotherapy or targeted therapies, and the impact on survival is pronounced compared to standard treatments. Combined with a favorable toxicity profile PD-1 agents have been approved in the US for treatment of head and neck cancer. This presentation will provide an overview of available clinical data from multiple agents, and outline how to best use these novel medications, as well as a discuss side effect management, and patient selection/candidate biomarkers. Furthermore, while PD-1/PD-L1checkpoint blockade is active in HNC and non-cross-resistant with other treatment modalities, much remains unknown: I will review strategies and ongoing trials, attempting to integrate immunotherapy in earlier lines of therapy, including curative intent, and adjuvant therapy. I will specifically review how immunotherapy may be complementary with surgical care, as well as potentially radiation, and chemo-prevention. Finally we will look ahead at upcoming second generation combination immunotherapy approaches, with early data suggesting that continued progress is ahead for our patients with oral cavity cancers and head and neck cancers in general.
July 03, 2017 There had been a service stop from Jul 2, 2017, 8:06 to Jul 2, 2017, 19:12(JST) (Jul 1, 2017, 23:06 to Jul 2, 2017, 10:12(UTC)) . The service has been back to normal.We apologize for any inconvenience this may cause you.
May 18, 2016 We have released “J-STAGE BETA site”.
May 01, 2015 Please note the "spoofing mail" that pretends to be J-STAGE.